YOLFTbeta
45

ENCell Co., Ltd.

456070 · KQ · Healthcare / Biotechnology

4,335.00KRW-15.00 (-0.34%)

Price History

Full chart

Market Stats

Previous Close4,350.00
Open4,350.00
Day Range4,165.00 – 4,500.00
52-Week Range4,800.00 – 20,950.00
Volume19.00K
Market Cap66.01B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.08
50-Day Avg5,837.90
200-Day Avg11,715.63

About

ENCell Co., Ltd. develops cell/gene-based biopharmaceutical products in South Korea. The company develops EN00, an allogeneic umbilical cord-derived mesenchymal stem cell treatment for Charcot-Marie-Tooth disease. It also provides contracting development and manufacturing services for biopharmaceutical products. The company was founded in 2018 and is based in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOJongwook Jang
  • Employees0
  • Headquarters701, Youngdong Daero, Seoul, South Korea, Korea
  • Websitehttps://encellinc.com

Leadership

  • Hong-bae JeonExecutive Director · b. 1976
  • Hyun-joong KimVice President
  • Jongwook JangChief Executive Officer

Financials

Income Statement

Currency: KRW2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue3.91B7.37B10.53B7.21B5.26B
Growth (%)-+88.49%+42.87%-31.51%-27.06%
Cost of Revenue2.74B6.70B10.88B10.19B7.66B
Gross Profit1.17B667.53M-357.56M-2.98B-2.40B
Gross Margin29.95%9.06%-3.40%-41.40%-45.68%
Operating Expense3.69B9.98B11.40B12.70B15.44B
Operating Income-2.52B-9.32B-11.76B-15.68B-17.84B
Operating Margin-64.55%-126.44%-111.69%-217.54%-339.26%
EBITDA--39.63B1.11B-10.29B-11.59B
EBITDA Margin--537.89%10.59%-142.72%-220.39%
Net Income-6.58B-45.57B-5.05B-15.21B-16.11B
Net Income Margin-168.32%-618.50%-48.01%-210.97%-306.30%
R&D2.10B5.73B6.07B6.64B7.73B
R&D as % of Total Revenue53.63%77.84%57.70%92.06%147.03%
Interest Expense1.81B2.98B1.93B422.19M614.38M
Interest Expense % of Total Revenue46.35%40.38%18.33%5.86%11.68%

Balance Sheet

Currency: KRW2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets38.57B54.75B43.98B55.75B63.71B
Total Liabilities42.20B78.58B5.96B7.58B24.31B
Total Equity-3.63B-23.84B38.02B48.17B39.40B
Cash5.90B5.78B12.69B30.58B38.51B

Cash Flow

Currency: KRW2021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-2.33B-6.96B-6.44B-10.10B-10.20B
Investing Cash Flow--14.71B14.29B4.86B-
Financing Cash Flow-21.56B-939.94M23.13B-
Capital Expenditure10.11B4.36B1.94B641.34M3.15B
Free Cash Flow-12.44B-11.32B-8.38B-10.74B-13.35B
FCF to OCF533.47%162.57%130.15%106.35%130.87%

Earnings

Report DateSep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate--------
EPS Actual-452.68-482.55-431.44-397.79-330.48-323.03-479.66-655.85
Surprise--------
Timing--------

Key Statistics & Ratios

Market Cap66.01B
Enterprise Value46.87B
Trailing P/E0.00
Forward P/E0.00
Price / Sales15.85
Price / Book2.34
Revenue (TTM)4.16B
Gross Profit (TTM)-2.83B
EBITDA-13.49B
Profit Margin0.00%
Operating Margin-539.02%
Return on Equity-57.72%
Return on Assets-22.30%
Shares Outstanding11.00M
Shares Float7.59M
Beta0.08
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%